Everist Genomics has received the U.S. Clinical Laboratory Improvement Amendment certification required for the company to launch its OncoDefender-CRC assay, a prognostic test for assessing the risk ...
SKY92 and next-generation sequencing (NGS) of bone marrow tumour cells into routine patient care for the first time in Ireland ...
Myriad Genetics (MYGN) announced that its Prolaris prostate cancer prognostic test continues to be classified by the National Comprehensive Cancer Network, NCCN, as an ‘Advanced Tool’ in the fight ...
SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for dermatology, hematology, and infectious & inflammatory diseases, announced today ...
SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that its Prolaris prostate cancer ...
At the San Antonio Breast Cancer Symposium, researchers presented a study on a multimodal artificial intelligence model that integrated clinical data, pathology-based imaging, and expanded molecular ...
Managing the invisible: Treatment approaches after pathological complete response (pCR) to neoadjuvant chemotherapy in oral cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I ...
Epigenetic test for risk-stratification impacts gastroenterologists' decision making and improves confidence when caring for patients with Barrett's esophagus. BALTIMORE, Oct. 28, 2024 /PRNewswire/ -- ...
The use of Renalytix plc’s Kidneyintelx biomarker-based prognostic test led to increased and targeted use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients at risk of diabetic kidney ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback